Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
11/06/14

Progress in Priority Portfolio Programs; Investor & Analyst Day Planned for December 12th

11/03/14

240 mg Achieved a Median Maximal Viral Load Decline of 4.9 Log10 IU/mL Following Three Daily Doses in Genotype 1a Patients

10/30/14
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/30/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its US operating subsidiary, Theravance Biopharma US, Inc. , that it will release financial results for the period ended September 30,
09/09/14

Plans for New Clinical Studies, Expanded Commercial Program and New Study Analyses Further Supporting Drug's in Vitro Potency in Resolving Difficult-to-Treat Infections

09/08/14

Primary and Secondary Efficacy Endpoints Met for Doses 88 mcg and Above; TD-4208 Demonstrates Clear Dose-Response Relationship and FEV1 Profile Consistent with Once-Daily Dosing

08/21/14
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/21/14 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Rick E Winningham, Theravance Biopharma's Chief Executive Officer, is scheduled to present at the following investor conferences in September 2014 : Baird 2014 Health Care
08/13/14

Separation Complete<br>Portfolio of Differentiated Assets Moving Forward<br>Investor & Analyst Day Planned for the Fourth Quarter

06/02/14
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/02/14 -- Theravance, Inc. (NASDAQ: THRX) ("Theravance") and Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") today announced the completion of the separation of Theravance Biopharma, Inc.